文献速递乳腺乳腺X线

数字乳腺断层合成联合合成乳腺摄影在乳腺癌检出中的重复筛查结果:前瞻性维罗纳试点研究

Repeat Screening Outcomes with Digital Breast Tomosynthesis Plus Synthetic Mammography for Breast Cancer Detection: Results from the Prospective Verona Pilot Study.
PubMed 文献 · Radiology · 2020-11-10

该前瞻性研究纳入34638名女性,比较数字乳腺断层合成联合合成乳腺摄影(DBT+SM)重复筛查与全视野数字乳腺摄影(FFDM)筛查的诊断准确性。重复筛查中DBT+SM的癌症检出率高于FFDM对照组(8.1 vs 4.5/1000,P<.01),召回阳性预测值更高(23.8% vs 12.0%,P<.01),且II期及以上癌症比例更低。

要点

  • 重复筛查中DBT+SM的癌症检出率为8.1/1000,高于FFDM对照组的4.5/1000(P<.01)。
  • 重复筛查中DBT+SM的召回阳性预测值为23.8%,高于FFDM对照组的12.0%(P<.01)。
  • 重复筛查中DBT+SM的II期及以上癌症比例为14.5%,低于FFDM对照组的27.3%(P≤.01)。

核心结论

  • 重复筛查中,数字乳腺断层合成联合合成乳腺摄影检出的癌症数量多于全视野数字乳腺摄影,且II期癌症数量低于全视野数字乳腺摄影。

研究设计与样本

  • 前瞻性研究(维罗纳试点研究,临床试验编号2015/1238),纳入2015年4月至2017年3月接受DBT+SM筛查、并于2017年4月至2019年3月接受DBT+SM或FFDM重复筛查的女性。

诊断标准与关键数值

  • 重复筛查DBT+SM组癌症检出率8.1/1000,FFDM对照组4.5/1000(P<.01)。
  • 重复筛查FFDM组癌症检出率3.5/1000,与FFDM对照组4.5/1000相比差异无统计学意义(P=.11)。
  • 重复筛查DBT+SM组召回率3.71%,FFDM对照组3.40%(P=.10),差异无统计学意义。
  • 重复筛查FFDM组召回率3.71%,FFDM对照组3.69%(P=.92),差异无统计学意义。
  • 重复筛查DBT+SM组召回阳性预测值23.8%,FFDM对照组12.0%(P<.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Few results are available about subsequent outcomes after screening with digital breast tomosynthesis (DBT). Purpose To compare the diagnostic accuracy of a screening round with DBT plus synthetic mammography (SM) (hereafter, DBT+SM) and the repeat screening round with DBT with SM (hereafter, DBT+SM) or full-field digital mammography (FFDM) with FFDM screening. Materials and Methods This prospective study (Verona Pilot Study, clinical trial identification: 2015/1238) included women screened with DBT+SM between April 2015 and March 2017 and rescreened with DBT+SM or FFDM between April 2017 and March 2019. Screening performance (recall rate, cancer detection rate [CDR], and positive predictive value of recall [PPV1]) was compared with that obtained from 28 680 women screened with FFDM between 2013 and 2014 (control group). Cancer stages were compared between modalities and screening rounds. A χ2 test was used to evaluate differences. P < .05 was indicative of a statistically significant difference. Results Of 34 638 women enrolled, 32 870 (median age, 58 years; age range, 52-71 years) underwent repeat screening-16 198 with DBT+SM and 16 672 with FFDM. The CDR was higher for repeat screening with DBT+SM than for the control group with FFDM (8.1 per 1000 women screened vs 4.5 per 1000 women screened, respectively; P < .01) and was not significantly lower for repeat screening with FFDM (3.5 per 1000 women screened vs 4.5 per 1000 women screened, respectively; P = .11). Compared with the control group, there was no difference in the recall rate at repeat screening with both DBT+SM (3.71% vs 3.40%, respectively; P = .10) and FFDM (3.71% vs 3.69%, P = .92), whereas PPV1 was higher only when repeat screening was performed with DBT+SM (23.8% vs 12.0%, P < .01). At repeat screening, the proportion of cancers stage II or higher was 14.5% (19 of 131 cancers) with DBT+SM and 8.5% (five of 59 cancers) with FFDM, both of which were lower than the proportion in the control group with FFDM (30 of 110 cancers, 27.3%) (P ≤ .01). Conclusion At repeat screening, digital breast tomosynthesis plus synthetic mammography depicted more cancers than full-field digital mammography (FFDM) and found a lower number of stage II cancers compared with FFDM. © RSNA, 2020 See also the editorial by Bae in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Caumo F, Montemezzi S, Romanucci G, et al. Repeat Screening Outcomes with Digital Breast Tomosynthesis Plus Synthetic Mammography for Breast Cancer Detection: Results from the Prospective Verona Pilot Study. Radiology. 2020. PMID: 33170101. doi:10.1148/radiol.2020201246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。